MIR100HG and colorectal carcinoma: This regulatory circuitry is clinically actionable as verified by the analysis of MIR100HG/hnRNPA2B1/TCF7L2 expression patterns in CRC specimens from patients whose tumors progressed on cetuximab and patients with lymph node or distant metastasis.